Stifel Raises Medivation Inc (MDVN) PT to $66 with Company In Play

Medivation (MDVN) PT Raised to $63 at Credit Suisse on M&A Valuation

May 3, 2016 7:27 AM EDT

Credit Suisse analyst Kenneth MacKay raised his price target on Medivation (NASDAQ: MDVN) to $63.00 (from $49.00) as he moves to a M&A valuation. The firm maintained an Outperform rating.

MacKay continues to see Sanofi's $52.50/share offer as significantly undervaluing the pipeline and continue to... More

Medivation (MDVN) PT Raised to $52 at Jefferies

May 2, 2016 7:47 AM EDT

Jefferies analyst Biren Amin raised his price target on Medivation (NASDAQ: MDVN) to $52.00 (from $39.00) following a Xtandi survey but maintained a Hold rating.

Amin commented, "We surveyed 50 physicians on current/projected Xtandi use and the trend appears to show increasing usage in most... More

UPDATE: AstraZeneca (AZN), Novartis (NVS),Pfizer (PFE) Said Among Firms Weighing Bids for Medivation (MDVN)

April 29, 2016 12:29 PM EDT

(Updated - April 29, 2016 12:32 PM EDT)

AstraZeneca (NYSE: AZN), Novartis (NYSE: NVS),Pfizer (NYSE: PFE) said among firms weighing bids for Medivation (NASDAQ:... More

Sanofi (SNY) Issues Commentary on Medivation's (MDVN) Rejection of Takeover Proposal; Remains Committed to Combination

April 29, 2016 9:06 AM EDT

Sanofi (NYSE: SNY) commented on Medivation, Inc.'s (Nasdaq: MDVN) rejection of Sanofi's non-binding all-cash proposal to acquire Medivation for $52.50 per share:

Combining Sanofi and... More

Medivation (MDVN) Rejects Sanofi's (SNY) Unsolicited Proposal

April 29, 2016 8:46 AM EDT

Medivation, Inc. (NASDAQ: MDVN) today announced that its Board of Directors, after consultation with its financial and legal advisors, unanimously determined that the unsolicited proposal from Sanofi (NYSE: SNY) to acquire Medivation for $52.50 per share in cash substantially undervalues Medivation and is not in the best interests of the company and its stockholders.

"Over the past several years, we have established a world class oncology franchise and a unique, diversified and highly-promising late-stage development pipeline," said David Hung, M.D., Founder, President and Chief Executive Officer of... More

Sanofi, Medivation dig in for big biotech takeover battle

April 29, 2016 4:11 AM EDT

By Matthias Blamont

PARIS (Reuters) - Sanofi and its takeover target Medivation (NASDAQ: MDVN) dug in for trench warfare on Friday, with the French drugmaker confident of winning over investors and the U.S. cancer firm insisting it was better off staying independent.

Sanofi, which has a track record of winning hostile fights in the biotech sector, said it was ready to speak directly to Medivation shareholders about its spurned $9.3 billion offer.

"While to date Medivation has chosen not to enter into discussions regarding this value-creating transaction, Sanofi remains committed to... More